Order and stock checks
Confirm order source, site, contact, product and quantity. Client-facing output: Dispatch record.
Clinical trial logistics
Site-level distribution of investigational products and materials with qualified packaging, temperature monitoring and documented proof of delivery across…
Site delivery
Confirm order source, site, contact, product and quantity. Client-facing output: Dispatch record.
Check lot/kit selection, status and expiry. Client-facing output: Packing/logger record.
Select configuration for route, season, duration and temperature. Client-facing output: Proof of delivery.
Apply second check to product, documents, seal and logger. Client-facing output: Exception or excursion file.
Client-anonymized operating experience
Client names remain private; vaccine studies are shown by name with their own project figures.
15–25 °C · Multi-site programme
Project scope224 centres · 164,733 participants · 247,435 medicine boxes
The project summary records medicine supply at 15–25 °C across a network involving 400 physicians and 650 assistant healthcare personnel. The box and participant figures belong to this past programme.
For sponsors: Site-level demand, stock units and the delivery calendar should be defined together at the start of scoping.
Distribution service15–25 °C · Early access
Project scope73 physicians · 900 medicines · 15–25 °C
A separate early-access summary reports that medicines held at ambient temperature were delivered to 73 physicians. Unlike multi-site study distribution, this example centres on a physician-level recipient plan.
For sponsors: Confirm the physician list, product quantity and authorised recipient before finalising dispatch.
Distribution service2–8 °C · Phase 3
Project scope24 sites · 26,180 vaccines · 2–8 °C
The Coronovac Phase 3 summary records a 24-site scope for vaccines with a 2–8 °C temperature profile. This quantity belongs to this Phase 3 study alone and is not combined with the other vaccine projects.
For sponsors: Site allocation and cold-chain requirements should be specified for each study and shipment plan.
Storage service2–8 °C · Phase 3
Project scope8 sites · 1,290 people × 2 administrations · 2,580 vaccines
The Turkovac Phase 3 summary lists 2,580 vaccines for two administrations to 1,290 people across eight sites under a 2–8 °C profile. Participant, administration and product counts are distinct planning inputs.
For sponsors: Calculate product demand from the administration schedule, not the site count alone.
Storage service2–8 °C · Phase 2b
Project scope41 sites · 4,340 vaccines · 2–8 °C
The Rapel Phase 2b summary records 4,340 vaccines across a 41-site study scope under a 2–8 °C profile. The breadth of the site network is a planning variable separate from product quantity.
For sponsors: Prepare site-level demand, delivery windows and recipient contacts separately.
Storage serviceSource: past project summaries supplied by Omega. Quantities and times describe only the relevant historical examples, not current capacity or a delivery commitment. The source does not distinguish vaccine doses from vials.
Short answer
Clinical distribution aligns an approved order with stock status, site, delivery window and temperature configuration through proof of delivery and exception closure.
Procurement brief
Distribution focuses on the right product reaching the right site, on time and within defined conditions.
RACI
Exception scenarios
Protect conditions and escalate redelivery or return.
Download data, block stock and send an assessment package.
Do not redirect until address and recipient are verified.
Operating model
Every project follows the same control logic, adapted to product and protocol requirements.
Confirm order source, site, contact, product and quantity.
Check lot/kit selection, status and expiry.
Select configuration for route, season, duration and temperature.
Apply second check to product, documents, seal and logger.
Track courier, delivery window and contact chain.
Record recipient, time, package condition and POD.
Escalate failed delivery or temperature events while protecting status.
Service-specific FAQ
Feasibility follows checks of stock, cut-off, route, packing and site acceptance.
It depends on product risk, qualified packaging, route and sponsor instruction.
Secure hold, return or redelivery follows the approved instruction while status is protected.
After carrier evidence and delivery details are checked under the agreed reporting schedule.
The sponsor/CRO owns master data; Omega dispatches only against a verified current list.
Inside the facility
Omega Depot
Share the product, route and timeline; our team will map a workable operational flow.